

Oral Presentations
May 10, 2012
7pm Main Conference Room

Molecular targeted ultrasound imaging of avb3-integrins expressing microvessels in association with anti-NMP antibodies detects ovarian cancer at early stage

Animesh Barua

Departments of Pharmacology, Pathology and Obstetrics & Gynecology, Rush University, Chicago

Ovarian Cancer Survivors' Experiences of Self-Advocacy: A Focus Group Study

Teresa Hagan

University of Pittsburgh School of Nursing, Pittsburgh, PA

Sex-steroid hormones and epithelial ovarian cancer: a nested case-control study

Annekatriin Lukanova

Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany

Potential effect of the Risk of Ovarian Cancer Algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) Trial

Paul Pinsky

Division of Cancer Prevention, NCI

Monoclonal antibody-based immunotherapy of ovarian cancer: targeting of differentiated and cancer initiating cells with the B7-H3-specific mAb 376.96 and sunitinib

Donald Buchsbaum

Department of Radiation Oncology, University of Alabama at Birmingham

Meso-TR3: A Novel TRAIL-Based Targeted Therapeutic in Ovarian Cancer

Gunjal Garg

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis

PGE2 in ovarian cancer-associated immune dysfunction

Pawel Kalinski

University of Pittsburgh Cancer Institute, Pittsburgh, PA

A genetically engineered mouse model for high grade serous "ovarian" carcinoma arising in the fallopian tube.

Ruth Perets

Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA